PCSK9 levels and diabetic retinopathy: opportunities for a potential target and novel therapeutic approach in conjunction with treating dyslipidaemia.
作者信息
Varughese Maria S, Nayak Ananth U, Jacob Sarita
机构信息
University of Sheffield Medical School, Royal Hallamshire Hospital, Sheffield, UK.
University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, North Staffordshire, UK.
出版信息
Eye (Lond). 2025 Mar;39(4):628-630. doi: 10.1038/s41433-024-03523-1. Epub 2024 Dec 2.
Abstract
摘要
相似文献
1
PCSK9 levels and diabetic retinopathy: opportunities for a potential target and novel therapeutic approach in conjunction with treating dyslipidaemia.前蛋白转化酶枯草溶菌素9水平与糖尿病视网膜病变：结合血脂异常治疗的潜在靶点及新治疗方法的机遇
Eye (Lond). 2025 Mar;39(4):628-630. doi: 10.1038/s41433-024-03523-1. Epub 2024 Dec 2.
2
The Predictive Utility of Circulating PCSK9 Levels on Diabetic Retinopathy Stage.循环 PCSK9 水平对糖尿病视网膜病变分期的预测价值。
Curr Eye Res. 2024 Oct;49(10):1107-1113. doi: 10.1080/02713683.2024.2386360. Epub 2024 Jul 31.
3
PCSK9 inhibition: from effectiveness to cost-effectiveness.前蛋白转化酶枯草溶菌素9（PCSK9）抑制：从有效性到成本效益
Front Cardiovasc Med. 2024 Jun 25;11:1339487. doi: 10.3389/fcvm.2024.1339487. eCollection 2024.
4
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.在患有糖尿病和血脂异常的人群中，丝氨酸蛋白酶 9 抑制剂的疗效和安全性。
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:39-51. doi: 10.1111/dom.13636.
5
Causal Association Between Cholesterol-Lowering Drugs and Diabetic Microvascular Complications: A Drug-Target Mendelian Randomization Study.降胆固醇药物与糖尿病微血管并发症之间的因果关联：一项药物-靶点孟德尔随机化研究。
J Diabetes Res. 2025 Feb 28;2025:3661739. doi: 10.1155/jdr/3661739. eCollection 2025.
6
The association of hypomagnesaemia, high normal uricaemia and dyslipidaemia in the patients with diabetic retinopathy.糖尿病视网膜病变患者低镁血症、尿酸水平略高于正常范围及血脂异常之间的关联。
J Clin Diagn Res. 2013 Sep;7(9):1852-4. doi: 10.7860/JCDR/2013/6106.3332. Epub 2013 Sep 10.
7
What else can we do to prevent diabetic retinopathy?我们还能做些什么来预防糖尿病视网膜病变？
Diabetologia. 2023 Sep;66(9):1614-1621. doi: 10.1007/s00125-023-05940-5. Epub 2023 Jun 6.
8
Diabetic dyslipidaemia.糖尿病血脂异常
Pract Lab Med. 2021 Jul 18;26:e00248. doi: 10.1016/j.plabm.2021.e00248. eCollection 2021 Aug.
9
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors.重度血脂异常的管理：前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的作用
Eur Cardiol. 2018 Aug;13(1):9-13. doi: 10.15420/ecr.2018.3.2.
10
Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.蛋白水解酶枯草溶菌素 9 在伴脊柱关节炎的血脂异常患者中与疾病活动度相关。
Rheumatology (Oxford). 2021 May 14;60(5):2296-2306. doi: 10.1093/rheumatology/keaa590.
引用本文的文献
1
Diabetic Retinopathy (DR): Mechanisms, Current Therapies, and Emerging Strategies.糖尿病视网膜病变（DR）：发病机制、当前治疗方法及新兴策略
Cells. 2025 Mar 4;14(5):376. doi: 10.3390/cells14050376.
2
Hybrid closed loop and intensive insulin delivery technology: Reviewing the effect of improving 'time in range' glucose levels on diabetic retinopathy.混合闭环与强化胰岛素输注技术：探讨改善血糖处于目标范围内的时间对糖尿病视网膜病变的影响
Eye (Lond). 2025 Apr;39(6):1028-1030. doi: 10.1038/s41433-025-03730-4. Epub 2025 Feb 20.
本文引用的文献
1
Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial.非诺贝特治疗对糖尿病视网膜病变进展的影响：通过LENS试验重新审视FIELD和ACCORD-EYE研究
Eye (Lond). 2025 Jan;39(1):15-17. doi: 10.1038/s41433-024-03410-9. Epub 2024 Oct 22.
2
Investigating the Relationship Between Lipid-Lowering Agents and the Complications of Diabetic Retinopathy.研究降脂药物与糖尿病视网膜病变并发症之间的关系。
Ophthalmic Surg Lasers Imaging Retina. 2024 Dec;55(12):706-713. doi: 10.3928/23258160-20240729-03. Epub 2024 Aug 1.
3
The Predictive Utility of Circulating PCSK9 Levels on Diabetic Retinopathy Stage.循环 PCSK9 水平对糖尿病视网膜病变分期的预测价值。
Curr Eye Res. 2024 Oct;49(10):1107-1113. doi: 10.1080/02713683.2024.2386360. Epub 2024 Jul 31.
4
Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression.非诺贝特在延缓糖尿病视网膜病变进展方面显示出前景。
NEJM Evid. 2024 Aug;3(8):EVIDe2400205. doi: 10.1056/EVIDe2400205. Epub 2024 Jul 23.
5
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.依洛尤单抗与急性冠脉综合征后性别及脂蛋白（a）对心血管结局的影响：来自 ODYSSEY OUTCOMES 研究的报告。
J Clin Lipidol. 2024 Jul-Aug;18(4):e548-e561. doi: 10.1016/j.jacl.2024.04.122. Epub 2024 Apr 10.
6
Effect of Fenofibrate on Progression of Diabetic Retinopathy.非诺贝特对糖尿病视网膜病变进展的影响。
NEJM Evid. 2024 Aug;3(8):EVIDoa2400179. doi: 10.1056/EVIDoa2400179. Epub 2024 Jun 21.
7
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review.针对已确诊冠心病或有冠心病高风险的糖尿病患者的经典及新型降脂疗法——一项叙述性临床综述
Pharmaceuticals (Basel). 2024 Apr 29;17(5):568. doi: 10.3390/ph17050568.
8
Genetic Association between Lipid-Regulating Drug Targets and Diabetic Retinopathy: A Drug Target Mendelian Randomization Study.脂质调节药物靶点与糖尿病视网膜病变之间的遗传关联：一项药物靶点孟德尔随机化研究
J Lipids. 2024 May 9;2024:5324127. doi: 10.1155/2024/5324127. eCollection 2024.
9
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.依洛尤单抗治疗强效且持久降低 LDL-C：ORION-8 试验。
Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109.
10
How safe are proprotein convertase subtilisinekexin type 9 inhibitors in diabetes?在糖尿病患者中，前蛋白转化酶枯草溶菌素 9 抑制剂的安全性如何？
Curr Opin Lipidol. 2024 Aug 1;35(4):187-194. doi: 10.1097/MOL.0000000000000934. Epub 2024 Mar 19.
Zotero 插件